Granted Patent
B2
US 10,294,296 · App. 13/215,464 · Granted May 21, 2019
Treatment for neoplastic diseases
Assignee:
XBiotech, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Administration of a mAb that specifically binds IL-1α is useful for treating tumor-associated diseases in human subjects.
Claims (2)
1. A method of reducing the size of a cancerous tumor in a human subject having cancer, the method comprising the step of administering to the subject a pharmaceutical composition comprising a pharmaceutically acceptable carrier and an amount of an anti-IL-1α antibody (Ab) effective to reduce the size of the cancerous tumor in the subject, wherein the size of the tumor in the subject is reduced, wherein the anti-IL-1α Ab is a monoclonal antibody (mAb), and wherein the mAb comprises a complementarity determining region of MABp1.
2. The method of claim 1 , wherein the mAb is MABp1.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jan 4, 2024
From: JANSSEN BIOTECH, INC.
To: XBIOTECH INC.
Reel/Frame 066022/0815 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Feb 10, 2020
From: XBIOTECH INC.
To: JANSSEN BIOTECH, INC.
Reel/Frame 051769/0927 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Sep 9, 2011
From: SIMARD, JOHN
To: XBIOTECH, INC.
Reel/Frame 026878/0015 →
Continuity (5)
Provisional Application
61376097
· Aug 23, 2010
Provisional Application
61406759
· Oct 26, 2010
Provisional Application
61411183
· Nov 8, 2010
Provisional Application
61480635
· Apr 29, 2011